Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 1.00 |
| ▸ | FNTB | P49356 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186537 | 1.00 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL5507286 | 0.93 | FNTA (0.87) | FNTAFNTBCYP3A4 | |
| SCHEMBL13573670 | 0.93 | FNTA (0.86) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954827 | 0.90 | FNTA (0.82) | FNTAFNTBCYP3A4 | |
| SCHEMBL13573613 | 0.89 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL4297501 | 0.89 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL4293521 | 0.89 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL4293520 | 0.89 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL3436599 | 0.89 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL5514757 | 0.89 | FNTA (0.80) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023209073-A1 | COMBINATION OF RAS INHIBITORS AND FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2023-11-02 | — | — | WO | disclosed |
| US-11542244-B2 | Synthesis of tipifarnib | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210246114-A1 | SYNTHESIS OF TIPIFARNIB | KURA ONCOLOGY, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| EP-1756085-B1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| EP-1162201-B1 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246114-A1 | SYNTHESIS OF TIPIFARNIB | TIPARP, RTF1, TTBK1 | FNTA 1300/4885FNTB 754/4885CYP3A4 1391/4885 |
| US-11542244-B2 | Synthesis of tipifarnib | TIPARP, RTF1, TTBK1 | FNTA 1300/4885FNTB 754/4885CYP3A4 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.